Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Zai Lab (NASDAQ:ZLAB) announced senior leadership changes to support operational performance and efficiency. The Board decided that President and COO Josh Smiley will leave the company, effective Friday, May 22.
Zai Lab expects multiple clinical data readouts in 2026 for lead global investigational therapies, including zoci in first-line ES-SCLC and extrapulmonary NECs, and ZL-1503 from a global Phase 1/1b study. The company is also preparing for the launch of COBENFY™ in China and for multiple anticipated regional regulatory approvals and data readouts.
Zai Lab (NASDAQ:ZLAB) received U.S. FDA Fast Track Designation for zocilurtatug pelitecan (zoci), a DLL3-targeting ADC, to treat extrapulmonary neuroendocrine carcinomas (epNECs) after progression on first-line therapy.
Zoci showed a 38.2% ORR and a manageable safety profile in an ongoing Phase 1b/2 trial and already holds Fast Track for ES-SCLC.
Zai Lab (NASDAQ: ZLAB) reported $99.6M total revenue for Q1 2026 and announced clinical and corporate updates on May 7, 2026. Key clinical highlights include zoci intracranial objective response of 62.5% at 1.6 mg/kg in SCLC with brain metastases and 38.2% confirmed ORR in epNECs. Zai Lab confirmed global collaborations with Amgen and Boehringer Ingelheim, registrational DLLEVATE enrollment on track to complete in H1 2027, and a Phase 1/1b ZL-1503 program with first-in-human data expected in 2H 2026.
Zai Lab (NASDAQ: ZLAB) will report first quarter 2026 financial results and provide corporate updates on May 7, 2026 before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET (8:00 p.m. HKT), with registration required and a replay available on the company website.
Investors can register via the provided webcast or dial-in links; dial-in details are sent after registration.
Zai Lab (NASDAQ: ZLAB) presented preclinical data at IMMUNOLOGY2026 showing that ZL-1503, an IL-13/IL-31Rα bispecific antibody, produced sustained, dose-dependent suppression of itch and Type 2 inflammation for 112 days after a single IV dose in non-human models.
The poster reported improved lung function and reduced airway inflammation at 10 mg/kg, broad TH2 pathway suppression, a favorable nonclinical safety profile, and that Phase 1/1b first-in-human studies began in December 2025 with clinical data expected in 2H 2026.
Zai Lab (NASDAQ: ZLAB) reported that zocilurtatug pelitecan (zoci), a DLL3-targeting ADC, produced a 53.7% confirmed intracranial objective response rate (iORR) in previously treated ES-SCLC with brain metastases; at 1.6 mg/kg confirmed iORR was 62.5% (10/16) including complete responses.
Preliminary epNEC data showed a 38.2% objective response rate. Safety was manageable; grade ≥3 TRAEs occurred in 19.9% overall. Global Phase 3 in second-line-plus SCLC is ongoing and registrational programs are planned in 2026.
Zai Lab and Amgen (NASDAQ: AMGN) announced a global clinical trial collaboration to test Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan (zoci), combined with Amgen’s FDA-approved Bispecific T-cell Engager IMDELLTRA® in extensive-stage small cell lung cancer (ES-SCLC).
Amgen will sponsor and lead a global Phase 1b study to evaluate safety and efficacy; Zai Lab will retain full ownership of zoci and supply the study drug. Prior Phase 1/2 data showed high response rates and strong intracranial activity for zoci.
Zai Lab (NASDAQ: ZLAB) will present data on three internally developed oncology candidates at AACR 2026, April 17-22 in San Diego. Posters cover zocilurtatug pelitecan (zoci), a DLL3-targeting ADC with intracranial activity in SCLC, ZL-6201, an LRRC15 ADC for sarcoma, and ZL-1222, a PD-1/IL-12 immunocytokine.
Zai Lab plans three registration-enabling studies for zoci across 2L+, 1L SCLC and extrapulmonary NECs by end of 2026.
Zai Lab (NASDAQ: ZLAB) reported Q4 2025 revenue $127.6M (+17% YoY) and FY2025 revenue $460.2M (+15% YoY). Product revenue growth was led by ZEJULA, XACDURO and NUZYRA. Net loss narrowed to $175.5M for FY2025 from $257.1M in FY2024. Cash and equivalents totaled $789.6M at year-end.
The company accelerated global oncology and immunology programs, highlighting zoci with three registration-enabling studies planned by end-2026, China approval and early 2026 launch plans for KarXT, and pivotal readouts for povetacicept and elegrobart in 2026.
Zai Lab (NASDAQ: ZLAB) will report its fourth quarter and full year 2025 financial results and provide corporate updates on February 26, 2026, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET (9:00 p.m. HKT). Participants must register in advance; a replay will be posted on the investor website.
Webcast registration is available via the company’s investor site and provided links; dial-in details are sent after registration.